{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:53:44Z","timestamp":1774565624955,"version":"3.50.1"},"reference-count":50,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>Immunoglobulin (Ig) therapy is the first\u2010line treatment and often the single option for a substantial number of diseases. Still, Ig supply and use have experienced restrictions, aggravated during the COVID\u201019 pandemic. This study assessed the clinical and economic implications of Ig use under restrictive conditions in neurological diseases and immunodeficiencies in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Hospitalization cases in neurological disorders and immunodeficiencies in which Ig is the main therapeutic option, identified by ICD\u201010 codes, were retrieved from the Spanish Minimum Basic Data Set for 2019 and 2022. Comorbidities and outcomes were analyzed along with hospitalization rates and characteristics, like the length of stay (LoS) and costs, among others. Therapeutic plasma exchange (TPE) use was evaluated as the alternative treatment of choice in the conditions analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 2022 compared to 2019, hospitalizations due to relapses remained stable in patients with neurological conditions. Comorbidity and complications increased significantly in this group, as well as LoS, mofrtality (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 for all), and TPE rates (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). These changes were not identified for immunodeficiencies, which only experienced a decrease in hospitalization rates (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Hospital costs increased in both groups (7.97% in neurological conditions and 2.41% in immunodeficiencies).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a period in which access to Ig may have been limited, neurological patients, but not patients with immunodeficiencies, show an increase in LoS and mortality, as well as an increased TPE. These results suggest that modifying the management strategy of patients with neurological disorders requiring Ig due to restrictive conditions could have negatively impacted their clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.70570","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T05:48:21Z","timestamp":1773640101000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Economic Implications of Immunoglobulin Use Under Restrictive Conditions in Adult Patients With Neurological Diseases and Immunodeficiencies in Spain"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis","family":"Querol","sequence":"first","affiliation":[{"name":"Neuromuscular Diseases Unit, Department of Neurology Hospital de la Santa Creu i Sant Pau (IR SANT PAU)  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Bruno","family":"Montoro\u2010Ronsano","sequence":"additional","affiliation":[{"name":"Pharmacy Department Vall D'hebron University Hospital  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0346-5570","authenticated-orcid":false,"given":"Pere","family":"Soler\u2010Palac\u00edn","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall D'hebron University Hospital  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Galduf","sequence":"additional","affiliation":[{"name":"CSL Behring Espa\u00f1a S.A.  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4510-0154","authenticated-orcid":false,"given":"\u00d3scar","family":"Mart\u00ednez\u2010P\u00e9rez","sequence":"additional","affiliation":[{"name":"Axentiva Solutions S.L.  Barcelona Spain"},{"name":"Applied Economics and Quantitative Methods, University of La Laguna  Tenerife Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"D\u00edaz\u2010Cuervo","sequence":"additional","affiliation":[{"name":"Axentiva Solutions S.L.  Oviedo Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Web Annex A \u201cWorld Health Organization Model List of Essential Medicines\u201323rd List. The Selection and Use of Essential Medicines 2023: Executive Summary of the Report of the 24th WHO Expert Committee on the Selection and Use of Essential Medicines \u201d(2024) https:\/\/www.who.int\/publications\/i\/item\/WHO\u2010MHP\u2010HPS\u2010EML\u20102023.02."},{"key":"e_1_2_12_3_1","unstructured":"Asociaci\u00f3n Espa\u00f1ola de D\u00e9ficit Inmunitarios Primarios (AEDIP) \u201cConsenso Espa\u00f1ol Por La Suficiencia de Plasma y Sus Tratamientos Derivados \u201d(2022)."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10875\u2010019\u201000737\u2010X"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ENE.16439"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ENE.16365"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/MUS.27046"},{"key":"e_1_2_12_8_1","unstructured":"Immune Deficiency Foundation \u201cWhat is PI? \u201d(2025) https:\/\/primaryimmune.org\/understanding\u2010primary\u2010immunodeficiency\/what\u2010is\u2010pi."},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANAI.2021.08.413\/ASSET\/BB756989\u201058E3\u20104893\u2010A6AE\u201052BE5946D5D5\/MAIN.ASSETS\/GR2.JPG"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLIM.2010.06.012"},{"issue":"3","key":"e_1_2_12_11_1","article-title":"Intravenous Immunoglobulin for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta\u2010Analysis","volume":"4","author":"Gaebel K.","year":"2010","journal-title":"Open Medicine"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/TRF.14656"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1807328"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0247717"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000199723"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.124999"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2018.1538001"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10875\u2010016\u20100279\u20100\/FIGURES\/6"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1413231"},{"key":"e_1_2_12_20_1","unstructured":"Marketing Research Bureau \u201cData & Analysis of Immunoglobulin Supply and Plasma Requirements in Europe 2010\u20102021 \u201d(2025) https:\/\/marketingresearchbureau.com\/wp\u2010content\/uploads\/2023\/05\/MRB_EU_SOHO_Figures\u20102023.pdf."},{"key":"e_1_2_12_21_1","unstructured":"T.Kluszczynski S.Rohr andR.Ernst \u201cWhite Paper \u201cKey Economic and Value Considerations for Plasma\u2010Derived Medicinal Products(PDMPs) in Europe \u201d(2020) https:\/\/www.vintura.com\/news\/white\u2010paper\u2010key\u2010economic\u2010value\u2010considerations\u2010plasma\u2010derived\u2010medicinal\u2010products\u2010pdmps\u2010europe\/."},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRACLI.2020.12.005"},{"key":"e_1_2_12_23_1","unstructured":"AEMPS \u201cProblemas de Suministro de Medicamentos \u201d(2024) https:\/\/www.aemps.gob.es\/profesional\u2010sanitario\/problemas\u2010de\u2010suministro\u2010de\u2010medicamentos\/."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.EIMC.2020.07.001"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.893770"},{"key":"e_1_2_12_26_1","unstructured":"Hospital Universitario Del 12 de Octubre. Salud Madrid \u201cProtocolo Local Para El Uso Racional de Inmunoglobulinas en El Hospital \u201d(2020)."},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRANSCI.2016.01.003"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000988"},{"key":"e_1_2_12_29_1","article-title":"Real Decreto 69\/2015, de 6 de Febrero, Por El Que Se Regula El Registro de Actividad de Atenci\u00f3n Sanitaria Especializada","volume":"35","author":"Ministerio de Sanidad Servicios Sociales e Igualdad","year":"2015","journal-title":"Bolet\u00edn Oficial Del Estado (BOE)"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rccl.2024.02.006"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216372"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895\u20104356(94)90129\u20105"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/JCA.22043"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rceng.2025.502284"},{"key":"e_1_2_12_36_1","unstructured":"Subdirecci\u00f3n General de Informaci\u00f3n Sanitaria. Ministerio de Sanidad \u201cProceso de Estimaci\u00f3n de Pesos y Costes Hospitalarios Del SNS. Pesos y Costes de SNS_2022 \u201d(2024)."},{"key":"e_1_2_12_37_1","unstructured":"Grupo Espa\u00f1ol de Medicamentos Hemoderivados Sociedad Espa\u00f1ola de Farmacia Hospitalaria \u201cGu\u00eda Cl\u00ednica Para el Uso de Inmunoglobulinas. Adaptaci\u00f3n Para Espa\u00f1a \u201d(2025) https:\/\/www.sefh.es\/bibliotecavirtual\/Guia_Igb\/Guia_Imnunoglobulinas.pdf."},{"key":"e_1_2_12_38_1","unstructured":"L.Leache M.Gutierrez L. C.Saiz andJ.Erviti \u201cEficacia y Seguridad de Las Inmunoglobulinas en Patolog\u00edas Neurol\u00f3gicas y Hematol\u00f3gicas. Mejora de La Adecuaci\u00f3n de La Pr\u00e1ctica Asistencial y Cl\u00ednica (MAPAC) \u201d(2023)."},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.ENSCI.2023.100468"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231154306\/ASSET\/IMAGES\/LARGE\/10.1177_17562864231154306\u2010FIG1.JPEG"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2147827"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/JCA.20217"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.788912"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN\u20102022\u2010061208"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ANA.22139"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.3233\/RNN\u2010231369"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1159\/000445414"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/ENE.14959"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203273"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.4103\/NSN.NSN_175_22"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00415\u2010020\u201009998\u20108"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70570","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.70570","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:13:46Z","timestamp":1774563226000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/ene.70570"],"URL":"https:\/\/doi.org\/10.1111\/ene.70570","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70570"}}